Compare Amylx Pharmaceuticals Inc (AMLX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.45. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | XDTE | |
|---|---|---|
Market Cap | $2.53B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $24.19 | $44.76 |
52-Week Low | $7.82 | $36.00 |
Enterprise Value | $2.28B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
XDTE trades at $39.46, up 0.65% with bullish technical signals from moving averages. The ETF generates weekly dividend distributions but faces scrutiny over yield sustainability and NAV erosion despite S&P 500 highs. Recent coverage highlights structural concerns about whether distributions represent true income or return of capital.
The fund offers high weekly income but carries significant risks including potential capital erosion and tax inefficiency. While technical momentum appears positive, fundamental concerns about the covered call strategy's long-term viability warrant caution for income-focused investors seeking sustainable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
